PDUFA Oct. 17, 2023 expectations

Quote

anonymous

Guest
The small biopharmaceutical company had flirted around the $1 billion market cap level, achieving a 52-week high of $5.13 (+34%) since last coverage. The FDA settled on a class 2 review and set a Prescription Drug User Fee Act (PDUFA) goal date of October 17, 2023, causing shares to tank 12%. This is an overreaction, and while the stock may remain volatile until PDUFA, investors should be reassured that XPHOZAH will most likely be approved into a huge market with no options.
 






Such exciting times! The dialysis patients want more pills, doctors want more prior auths and diarrhea is everyone’s favorite! This drug is going to kill it, could be a blockbuster?!?
 












The market is clamoring for this drug! The efficacy numbers from the trials along with tolerability was outstanding. All of the patients will now reach their phosphorus goals.
 






Top Bottom
Back
Quote